Imaging Depression in Parkinson's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

December 31, 2029

Conditions
Parkinson's DiseaseMajor Depressive Disorder
Interventions
RADIATION

11C-UCB-J

Radiotracer for imaging

DRUG

ketamine hydrochloride

There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.

Trial Locations (1)

06520

RECRUITING

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Yale University

OTHER